Ubs Group Ag Akero Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 94,801 shares of AKRO stock, worth $2.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,801

Previous 71,111 33.31%

Holding current value

$2.68 Million

Previous $1.67 Million 63.01%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.45 - $29.34 $508,150 - $695,064	23,690 Added 33.31%	94,801 $2.72 Million
Q2 2024 Aug 13, 2024	SELL	$18.31 - $24.62 $2.51 Million - $3.37 Million	-136,890 Reduced 65.81%	71,111 $1.67 Million
Q1 2024 May 13, 2024	SELL	$17.76 - $31.18 $1.04 Million - $1.82 Million	-58,385 Reduced 21.92%	208,001 $5.25 Million
Q4 2023 Feb 09, 2024	BUY	$11.38 - $50.33 $2.37 Million - $10.5 Million	207,983 Added 356.12%	266,386 $6.22 Million
Q3 2023 Nov 09, 2023	BUY	$41.19 - $52.25 $1.32 Million - $1.67 Million	31,968 Added 120.93%	58,403 $2.95 Million
Q2 2023 Aug 11, 2023	SELL	$36.89 - $56.88 $2.47 Million - $3.81 Million	-66,997 Reduced 71.71%	26,435 $1.23 Million
Q1 2023 May 12, 2023	SELL	$37.27 - $50.24 $1.7 Million - $2.29 Million	-45,548 Reduced 32.77%	93,432 $3.57 Million
Q4 2022 Feb 08, 2023	BUY	$33.44 - $54.8 $4.52 Million - $7.41 Million	135,262 Added 3638.03%	138,980 $7.62 Million
Q3 2022 Nov 10, 2022	BUY	$10.15 - $34.05 $2,212 - $7,422	218 Added 6.23%	3,718 $127,000
Q2 2022 Aug 10, 2022	SELL	$8.0 - $15.01 $504,520 - $946,605	-63,065 Reduced 94.74%	3,500 $33,000
Q1 2022 May 16, 2022	BUY	$12.97 - $22.26 $126,133 - $216,478	9,725 Added 17.11%	66,565 $945,000
Q4 2021 Feb 14, 2022	BUY	$19.87 - $26.24 $269,993 - $356,549	13,588 Added 31.42%	56,840 $1.2 Million
Q3 2021 Nov 15, 2021	BUY	$18.65 - $25.46 $614,536 - $838,932	32,951 Added 319.88%	43,252 $967,000
Q2 2021 Aug 13, 2021	SELL	$24.81 - $32.35 $454,221 - $592,263	-18,308 Reduced 63.99%	10,301 $255,000
Q1 2021 May 12, 2021	BUY	$24.04 - $34.19 $539,818 - $767,736	22,455 Added 364.88%	28,609 $830,000
Q4 2020 Feb 11, 2021	BUY	$25.12 - $29.89 $112,110 - $133,399	4,463 Added 263.93%	6,154 $159,000
Q3 2020 Nov 12, 2020	BUY	$30.79 - $39.92 $7,358 - $9,540	239 Added 16.46%	1,691 $52,000
Q2 2020 Jul 31, 2020	BUY	$19.25 - $26.76 $8,489 - $11,801	441 Added 43.62%	1,452 $36,000
Q1 2020 May 01, 2020	SELL	$12.8 - $27.05 $28,800 - $60,862	-2,250 Reduced 69.0%	1,011 $21,000
Q4 2019 Feb 14, 2020	SELL	$17.37 - $27.27 $49,452 - $77,637	-2,847 Reduced 46.61%	3,261 $72,000
Q3 2019 Nov 14, 2019	BUY	$16.89 - $29.88 $84,281 - $149,101	4,990 Added 446.33%	6,108 $139,000
Q2 2019 Aug 14, 2019	BUY	$18.08 - $19.83 $20,213 - $22,169	1,118 New	1,118 $21,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.31B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account